<?xml version="1.0" encoding="UTF-8"?>
<svg height="769.854" width="552.8666293333333" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <text x="70.276,75.661,78.484,81.484,82.984,87.524,89.71,92.511,94.179,95.679,99.055,101.822,103.652,106.661,108.329,109.829,114.368,116.554,119.355,121.023,122.523,126.551,128.449,130.447,131.947,136.043,139.16,141.949,144.751,146.507,148.007,149.507,152.597,155.416,158.291,161.291,162.791,168.248,171.122,173.12,174.62,177.449,179.234,182.331,185.331,186.831,188.766,191.611,193.563,195.147,197.843,200.638,203.329,206.251,208.073,211.124,214.139,215.639,217.139,218.639,220.139,221.639,223.139,224.639,226.139,227.639,229.139,230.639,232.139,233.639,235.139,236.639,238.139,239.639,241.139,242.639,244.139,245.639,247.139,248.639,250.139,251.639,253.139,254.639,256.139,257.639,259.139,260.639,262.139,263.639,265.139,266.639,268.139,269.639,271.139,272.639,274.139,275.639,277.139,278.639,280.139,281.639,283.139,284.639,286.139,287.639,289.139,290.639,292.139,293.639,295.139,296.639,298.139,299.639,301.139,302.639,304.139,305.639,307.139,308.639,310.139,311.639,313.139,314.639,316.139,318.367,323.148,326.173,327.952,330.821,333.891,335.753,338.087,339.587,341.48,344.48,345.98,349.105,351.872,353.753,355.468,358.297,361.366,363.228,365.562,367.062,371.594,373.313,375.183,378.183,379.683,382.787,384.972,387.774,389.442,390.942,395.762,398.632,401.849,403.665,405.693,408.519,410.97,412.873,415.64,417.521,419.23,422.336,425.515,427.849,429.349,432.334,434.332,435.832,438.604,441.7,443.53,446.571,448.458,453.398,458.14,461.392,464.492,467.156,468.656,471.76,473.758,475.258,479.999,483.116,485.921,489.157,491.395,494.191,497.287,499.189,502.059,505.16,507.983,511.07,514.257,516.591,518.091,521.292,523.083,525.539,528.356,531.204,533.659,536.484" y="44.424999999999955" svg_rhmargin="538.818" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:6.0px;font-style:NORMAL;font-weight:normal;">Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24 (2):e217-30. Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases</text>
  <text x="296.941,300.493,304.493,308.493" y="759.854" svg_rhmargin="312.493" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:8.0px;font-style:NORMAL;font-weight:normal;">e220</text>
  <text x="70.866,74.259,78.651,83.69,88.327,91.676,96.854,99.855,104.83,109.83,112.29,117.179,123.245,128.121,130.621,133.081,138.443,141.091,146.688,149.188,151.648,157.777,164.435,166.935,169.395,174.023,179.014,184.014,186.474,190.376,195.947,200.387,202.847,209.909,214.474,217.867,222.307,224.767,229.332,232.725,237.261,241.701,244.601,249.147,254.239,256.739,259.199,265.551,270.542,274.982,277.442,281.12,286.39,291.473" y="84.09900000000005" svg_rhmargin="294.803" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">regarding oLp, SjS, EB, and sSc were created. The fun-</text>
  <text x="70.866,75.866,80.199,82.979,85.479,86.319,91.184,93.877,98.839,101.619,104.119,104.959,108.352,112.792,117.632,122.167,126.674,129.376,133.922,138.922,141.422,142.262,145.224,150.311,154.751,157.531,160.031,160.871,163.833,168.824,173.389,176.782,181.222,183.722,184.562,187.384,191.274,193.774,194.62,199.611,204.611,207.111,207.951,212.391,217.564,220.266,225.3,229.854,234.869,239.366,243.806,246.306,247.146,250.321,255.321,258.651,261.151,261.991,266.966,272.01,276.875,279.785,282.482,286.964,291.473" y="96.09900000000005" svg_rhmargin="294.803" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">nel plot revealed that there is no evidence for publica-</text>
  <text x="70.866,73.847,76.521,81.531,86.531,89.261,94.188,96.968,101.556,105.446,108.176,111.042,114.372,117.102,120.278,125.253,130.533,133.863,136.593,141.568,146.612,151.477,154.387,157.084,161.566,166.006,168.987,171.66,176.67,181.809,185.699,188.429,195.49,200.055,203.448,207.888,210.613,215.029,219.844,224.128,226.863,231.906,236.94,241.486,246.486,249.216,252.865,256.233,261.233,269.013,271.738,279.518,283.996,287.016,291.49" y="108.09900000000005" svg_rhmargin="294.82" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">tion bias if four publications were excluded from meta-</text>
  <text x="70.866,75.493,80.59,85.096,87.807,92.826,96.65,99.472,103.354,105.854,108.732,113.941,118.941,122.334,126.883,130.804,133.584,136.46,141.326,144.019,148.981,151.928,155.818,158.698,162.575,167.556,172.396,179.457,184.003,189.003,191.881,196.776,201.52,209.85,212.729,217.24,222.25,227.569,233.03,238.064,242.618,247.633,252.13,256.57,259.446,262.448,267.393,270.293,274.858,278.584,283.559,288.065,290.906,294.796" y="120.09900000000005" svg_rhmargin="297.296" style="fill:#171615;font-family:CRUCZX+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">analysis. Forest plots showed 95% confidence intervals </text>
  <text x="70.866,74.041,79.041,82.371,84.871,85.491,88.453,93.445,97.885,100.385,101.005,106.103,111.18,116.015,118.718,123.263,128.263,130.763,131.383,134.374,142.178,147.043,149.841,154.468,159.413,162.193,164.693,165.313,168.653,173.169,176.05,178.785,184.065,187.458,191.898,194.398,195.018,198.502,202.942,205.843,210.283,212.783,213.403,218.502,223.067,226.397,228.897,229.517,234.377,238.912,243.55,246.88,249.38,250.0,254.627,259.618,264.618,267.118,267.738,270.913,275.913,279.243,281.743,282.363,285.325,290.316,294.756" y="132.09900000000005" svg_rhmargin="297.256" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">for the pooled implant failure rate per year and for the </text>
  <text x="70.866,74.206,78.723,81.603,84.338,89.618,93.011,97.451,99.641,103.125,107.565,110.465,114.905,117.095,121.887,125.217,127.407,131.943,136.512,140.908,145.908,148.098,152.018,155.14,160.183,165.211,169.562,172.062,174.252,183.037,188.037,191.43,195.975,200.806,205.646,210.211,213.251,215.751,217.941" y="144.09900000000005" svg_rhmargin="221.271" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">failure rate of each study. Moreover, I</text>
  <text x="221.498" y="140.769" svg_rhmargin="224.413" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:5.83px;font-style:NORMAL;font-weight:normal;">2</text>
  <text svg_rhmargin="294.803" y="84.09900000000005" x="226.603,229.484,237.264,241.799,246.388,250.351,255.631,259.024,263.464,265.654,268.829,273.829,277.159,279.349,284.34,288.817,291.473,294.803" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">(measure for het- </text>
  <text x="314.646,319.211,322.579,327.486,332.428,336.982,341.982,346.422,349.114,352.211,356.761,360.091,362.591,369.788,374.376,378.266,380.766,385.251,389.757,392.445,396.942,402.092,404.89,409.33,412.23,416.775,421.775,424.275,427.45,432.45,435.78,438.28,442.816,447.385,451.781,456.781,459.281,467.061,471.539,474.559,479.034,482.433,487.06,492.156,496.663,499.374,504.393,508.216,511.039,514.92,517.42" y="84.09900000000005" svg_rhmargin="519.92" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">erogeneity) was calculated for each meta-analysis. </text>
  <text x="314.646,320.997,325.988,330.428,332.452,336.373,339.393,343.833,346.814,349.636,353.557,356.538,359.236,363.718,368.224,371.004,373.028,377.655,382.752,387.258,389.969,394.988,398.812,401.634,405.524,407.554,414.751,419.339,423.229,425.259,429.742,434.379,438.115,441.739,444.423,448.968,453.968,455.998,460.973,465.961,468.741,470.765,475.919,479.743,482.744,487.719,492.719,494.744,500.19,505.713,511.224,516.784,518.814,523.781,528.834,531.169,536.091,538.591" y="96.09900000000005" svg_rhmargin="541.091" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">The statistical analysis was carried out using SPSS 22.0, </text>
  <text x="314.646,321.316,323.816,328.656,333.22,336.71,340.533,343.206,348.216,353.216,355.716,360.407,362.784,367.657,370.174,375.174,377.674,382.302,387.293,392.293,394.793,397.755,402.746,407.186,409.686,416.356,418.856,423.9,428.469,432.855,438.0,442.482,447.424,451.864,454.364,458.855,466.635,471.113,474.133,478.396,482.197,484.697" y="108.09900000000005" svg_rhmargin="487.197" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">R version 3.4.3 and the R package “meta”. </text>
  <text x="314.646,320.093,324.572,329.437,332.139,336.579,339.089,344.243,346.743,349.253,354.253,356.763,361.274,366.284,371.229,374.211,377.212,382.165,387.18,391.62,394.12,396.63,401.63,404.14,408.652,413.662,418.607,421.588,424.589,429.542,434.557,439.204,442.058,447.058,449.568,454.08,459.09,464.035,467.055,471.572,474.573,479.712,483.602,486.112,489.074,494.065,498.505,501.015,506.384,513.412,516.729,522.174,531.366,538.586" y="120.09900000000005" svg_rhmargin="541.086" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">Table 2, 2 continue, 2 continue-1 contains the PRISMA </text>
  <text x="314.646,319.041,324.032,328.594,332.979,338.225,341.135,343.957,347.878,350.658,353.158,354.038,357.431,361.822,366.861,371.499,374.848,380.026,383.027,388.002,393.002,395.502,396.382,399.344,404.335,408.775,411.275,412.155,419.935,424.412,427.375,432.356,437.433,442.458,447.293,449.986,454.893,460.183,465.183,467.683,468.563,473.355,476.685,479.185,480.065,483.027,488.018,492.458,494.958,495.838,499.778,504.797,508.717,511.618,516.163,524.039,528.479,531.46,534.158,538.598" y="132.09900000000005" svg_rhmargin="541.098" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">checklist regarding the methodology of the systematic </text>
  <text x="314.646,318.039,322.479,327.652,330.335,334.783,342.003,344.503,349.552,352.92,358.013,362.51,367.059,371.014,374.904,377.404,382.033,387.024,392.024,394.524,399.736,404.176,407.196,411.636,414.136,418.763,423.858,428.365,431.076,436.095,440.022,444.571,448.453,450.953,453.453" y="144.09900000000005" svg_rhmargin="455.953" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:10.0px;font-style:NORMAL;font-weight:normal;">review process and data analyses. </text>
  <text x="76.991,82.117,86.262,90.406,93.689,96.256,100.769,105.773,108.023,110.525,112.775,115.869,120.401,125.422,127.981,131.977,285.41,289.406,294.41,298.555,302.551,307.922,310.705,313.355,316.92,319.917,322.167,324.719,327.827,331.875,339.372,487.197,491.238,495.316,500.41,504.893,509.157,512.264,516.409,521.413,523.663,528.177,533.181" y="186.03099999999995" svg_rhmargin="535.431" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:9.0px;font-style:NORMAL;font-weight:bold;">Section / topic checklist item reported on </text>
  <text x="501.148,506.152,510.758,515.24" y="196.83100000000002" svg_rhmargin="519.236" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:9.0px;font-style:NORMAL;font-weight:bold;">page</text>
  <text x="76.991,81.491,83.741,85.991,88.241,90.491,93.206,95.663,98.255,100.724,104.72,149.025,152.26,159.318,163.734,166.287,170.483,174.97,177.656,181.157,183.407,186.14,190.64,192.89,197.465,201.5,204.215,206.668,210.8,215.287,217.973,221.474,223.724,230.413,232.872,235.57,240.07,242.32,246.861,250.03,254.12,256.622,258.872,265.991,270.188,274.907,277.519,280.44,284.569,288.131,290.882,294.915,297.631,300.074,304.619,309.279,312.78,315.03,319.381,322.378,324.628,328.672,333.198,335.831,340.274,342.999,350.309,357.304,362.077,366.613,370.609,372.859,377.399,380.396,382.646,389.641,394.203,398.298,403.045,406.298,410.379,414.905,417.656,421.852,426.388,430.512,435.025,439.696,443.197,445.447,450.141,452.716,456.285,460.4,464.563,468.131,472.26,475.761" y="211.07100000000003" svg_rhmargin="478.011" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">1 title Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases </text>
  <text svg_rhmargin="351.809" x="272.978,277.478,279.728,283.724,285.974,289.552,294.104,297.667,300.31,304.434,311.555,315.589,318.305,320.769,324.765,327.015,330.102,334.132,338.82,341.271,345.311,351.80899999999997" y="211.07100000000003" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">– a systematic review </text>
  <text x="507.94" y="211.07100000000003" svg_rhmargin="512.44" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">1</text>
  <text x="76.991,81.491,83.741,85.991,88.241,90.491,94.559,99.131,102.693,105.508,108.677,112.823,116.905" y="236.11199999999997" svg_rhmargin="119.407" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">2 abstract</text>
  <text y="246.91200000000003" svg_rhmargin="130.515" x="90.491,94.055,96.869,100.286,104.849,108.93,111.771,116.553,119.641,123.765,128.265" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">structured </text>
  <text svg_rhmargin="125.389" y="236.11199999999997" x="90.491,94.091,98.857,106.166,113.287,117.494,120.889,125.389" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">summary </text>
  <text x="151.639,158.421,161.13,168.528" y="236.11199999999997" svg_rhmargin="171.525" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:9.0px;font-style:NORMAL;font-weight:bold;">Aim:</text>
  <text y="236.11199999999997" svg_rhmargin="475.397" x="173.777,178.578,183.078,185.328,190.017,192.481,196.875,200.871,203.121,207.316,211.816,214.066,218.451,222.844,226.985,230.367,235.056,237.507,241.546,248.044,250.294,254.841,259.341,261.591,264.315,271.373,275.79,278.343,282.539,287.025,289.527,291.777,295.377,300.161,303.543,308.231,310.694,315.208,319.298,321.8,324.05,327.217,331.252,333.895,338.024,341.525,343.775,346.509,351.009,353.259,357.834,361.868,364.583,367.035,371.168,375.655,378.341,381.842,384.092,390.781,393.24,395.938,400.438,402.688,407.229,410.397,414.488,416.99,419.24,426.359,430.556,435.274,437.887,440.808,444.937,448.5,451.249,455.283,457.999,460.442,464.987,469.646,473.147" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">To give an overview on implant survival rates in patients with oral manifestations </text>
  <text x="155.532,159.883,162.88,165.13,168.71,173.262,176.825,179.468,183.592,190.811,193.277,197.273,199.523,203.564,208.091,210.724,215.166,217.891,225.201,232.196,236.97,241.506,245.502,247.752,250.296,254.837,258.005,262.095,264.597,266.847,272.304,274.768,278.759,283.287,287.42,291.92,294.17,298.586,301.139,305.336,309.829,314.501,318.002,320.252,322.798,327.236,332.735,336.779,339.677,341.927,344.177,349.03,353.154,360.212,364.727,369.437,371.867,376.68,381.351,384.852,387.102,390.326,395.18,398.744,401.306,404.205,406.455,408.705,415.7,420.262,424.356,429.104,432.356,436.439,440.965,443.714,447.911,452.447,456.571,461.083,465.755,469.256" y="246.91200000000003" svg_rhmargin="471.506" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">of systemic autoimmune (oral Lichen planus (oLp), Pemphigus (Pe)), muco-cutaneous </text>
  <text x="146.995,150.201,155.727,160.198,162.667,167.232,171.373,174.755,181.784,186.174,188.65,193.202,196.679,199.254,202.755,205.005,209.519,214.187,216.829,219.289,223.864,227.461,231.457,233.707,236.911,242.465,248.083,250.645,253.543,255.793,258.043,262.584,265.581,267.831,271.874,276.4,279.034,283.476,286.201,293.51,300.506,305.28,309.816,313.812,316.062,323.055,327.722,330.182,332.897,335.472,339.052,343.605,347.168,349.81,353.934,361.155,363.619,367.615,369.865,372.934,377.462,381.526,386.292,393.412,397.447,400.162,402.628,406.624,408.874,413.566,416.141,419.71,423.824,427.988,431.556,435.685,439.186,441.436,444.139,449.004,451.451,455.905,460.693,463.78,467.913,471.961,474.292,477.793" y="257.712" svg_rhmargin="480.043" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">(Epidermolysis bullosa (EB)), or autoimmune multisystemic rheumatic diseases (Sjögren´s </text>
  <text x="146.031,149.612,154.419,158.946,163.747,166.812,171.344,178.381,182.377,184.627,187.329,192.193,194.615,199.529,202.427,204.677,206.927,210.507,215.06,218.623,221.265,225.389,232.61,235.074,239.07,241.32,246.807,251.376,255.889,260.561,264.062,266.312,270.453,273.848,278.677,281.376,285.904,290.028,297.15,301.183,303.882,308.401,312.975,316.577,321.249,324.75,327.0,329.554,333.062,338.604,344.063,346.961,349.211,351.461,356.002,358.999,361.249,364.828,369.38,372.943,375.586,379.71,386.93,389.394,393.39,395.64,400.69,404.583,407.051,411.193,414.259,418.833,422.311,424.886,428.387,430.637,433.191,436.738,441.788,445.335,447.897,450.756" y="268.51199999999994" svg_rhmargin="453.006" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">syndrome (SjS), systemic Lupus erythemathosus (sLE), or systemic Sclerosis (sSc)).</text>
  <text y="268.51199999999994" svg_rhmargin="478.756" x="455.251,463.825,468.316,471.423,475.759" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:9.0px;font-style:NORMAL;font-weight:bold;">Mate-</text>
  <text x="146.861,151.112,153.718,158.363,160.865,163.115,167.7,172.704,177.708,179.958,188.427,192.494,195.558,200.552,205.167,210.273,213.659" y="279.312" svg_rhmargin="216.656" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:9.0px;font-style:NORMAL;font-weight:bold;">rial and Methods:</text>
  <text y="279.312" svg_rhmargin="480.175" x="218.905,223.878,228.43,231.993,234.635,238.76,245.881,249.915,252.631,255.095,259.091,261.341,263.991,266.45,269.094,273.234,276.403,280.438,283.278,288.061,291.148,295.144,297.394,300.48,304.51,309.199,311.651,315.689,322.187,324.437,327.662,332.916,337.489,341.943,349.899,354.023,358.871,361.702,369.657,373.782,378.466,381.118,383.85,388.386,392.42,394.67,396.92,402.462,409.47,414.025,418.188,421.756,425.32,428.317,430.567,435.239,438.717,441.449,445.963,450.463,452.713,460.962,466.491,471.427,477.925" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Systematic literature review (PubMed/Medline, Embase) using MESH </text>
  <text x="153.033,157.229,161.756,166.256,168.506,172.075,176.19,180.396,183.479,187.471,191.971,194.221,196.863,201.004,204.386,211.388,213.638,217.731,222.263,229.271,233.742,236.475,241.095,245.129,247.845,250.288,254.833,259.492,263.095,265.345,267.595,272.108,276.681,281.097,283.748,286.323,289.848,294.376,298.499,302.999,305.249,309.854,313.919,316.733,323.127,327.252,331.385,335.885,338.135,342.31,346.743,351.286,355.786,358.036,362.232,366.759,371.259,373.509,380.117,384.198,386.833,391.333,395.937,400.078,403.075,405.325,409.84,413.926,417.811,422.311,424.561,427.294,431.794,434.044,439.596,444.109,448.717,451.369,453.945,457.468,461.968,464.218,468.759,471.756" y="290.112" svg_rhmargin="474.006" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">and search term combinations, published between 1980 and October 2017 in English or </text>
  <text x="153.481,160.095,164.236,167.618,174.739,178.935,183.435,185.685,188.238,192.434,196.948,201.76,206.466,210.534,215.018,219.014,221.264,224.35,228.522,233.143,237.684,241.061,243.778,246.51,251.023,255.523,257.773,262.318,266.818,269.068,273.634,277.767,282.253,285.004,289.093,291.595,293.845,296.569,303.627,308.043,310.596,314.792,319.279,321.7,324.789,329.368,332.433,337.008,340.57,343.269,347.797,351.861,354.577,357.042,361.038,363.288,366.373,370.409,375.02,379.084,383.555,386.18,388.833,391.291,394.041,398.076,400.791,403.234,407.779,412.279,414.529,418.88,421.877,424.127,428.702,432.736,435.451,437.903,442.036,446.523,449.209,452.71,454.96,461.649,464.108,466.806,471.306" y="300.912" svg_rhmargin="473.556" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">German language reporting on dental implant-prosthetic rehabilitation of patients with </text>
  <text x="147.6,152.036,157.535,161.963,164.213,166.463,171.316,175.349,177.599,179.849,185.403,191.433,193.683,195.933,200.798,203.219,208.294,210.544,212.794,216.303,221.843,227.559,229.809,232.059,235.606,240.656,244.652,246.902,249.152,252.715,255.554,260.127,264.688,269.188,271.438,276.003,280.132,283.609,286.038,290.83,295.486,297.736,299.986,304.055,308.538,312.571,314.821,317.071,321.555,325.689,330.216,334.782,338.922,341.699,343.949,346.199,349.093,353.484,356.126,358.586,362.979,369.352,372.425,376.994,381.494,383.744,388.367,392.508,395.8,398.243,402.847,407.347,409.597,413.947,416.944,419.194,423.735,426.732,428.982,432.991,437.363,441.445,445.57,449.694,454.387,457.12,461.633,466.133,468.383,472.69,477.19" y="311.712" svg_rhmargin="479.44" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">oLp, Pe, EB, SjS, sLE, sSc, study design, age, gender, follow-up period of or exceeding 12 </text>
  <text x="149.435,156.463,161.008,165.495,168.194,172.844,176.345,178.595,182.793,187.32,191.82,194.07,196.794,203.852,208.268,210.821,215.017,219.504,222.006,224.256,227.856,232.639,236.021,240.709,243.173,247.686,251.777,254.279,256.529,259.696,263.731,266.373,270.334,272.584,274.834,282.819,286.853,289.283,293.997,298.525,302.648,307.148,309.398,316.436,320.551,324.748,329.248,331.498,336.011,340.101,342.599,347.147,351.276,354.777,357.027,361.38,364.377,366.627,369.351,376.409,380.825,383.379,387.574,392.061,394.563,396.813,400.413,405.196,408.579,413.267,415.73,420.243,424.334,426.836,429.086,432.253,436.288,438.93,442.926,445.176,447.802,454.579,461.678,466.613,472.355,475.352" y="322.512" svg_rhmargin="477.602" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">months and implant survival rate. Weighed mean values of implant survival rate (wmSR) </text>
  <text x="156.368,162.762,166.903,169.99,173.986,176.236,180.304,184.394,186.85,190.931,195.599,198.152,202.186,204.829,208.953,213.453,215.703,218.597,223.137,226.134,228.384,232.959,236.994,239.709,242.161,246.294,250.781,253.467,256.968,259.218,265.906,268.366,271.064,275.564,277.814,282.251,287.75,292.177,294.427,296.677,301.531,305.564,307.814,310.064,315.618,321.648,323.898,326.148,331.012,333.434,338.508,340.758,343.008,346.518,352.058,357.557,359.807,364.347,367.344,369.594,373.141,378.19,382.113,384.363" y="333.312" svg_rhmargin="386.613" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">were calculated for patients with oLp, Pe, EB, SjS, sLE or sSc. </text>
  <text x="386.61,393.103,397.261,400.772,405.963,408.519,411.678,415.064,418.061" y="333.312" svg_rhmargin="420.311" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:9.0px;font-style:NORMAL;font-weight:bold;">Results: </text>
  <text x="420.313,426.994,430.295,432.937,437.078,440.075,442.325,446.321,448.571,455.607,459.723,463.919,468.419" y="333.312" svg_rhmargin="470.669" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">After a mean </text>
  <text x="149.244,152.138,156.527,159.17,161.63,166.024,172.396,175.469,180.039,184.539,186.789,191.411,195.552,198.845,201.287,205.891,210.391,212.641,215.276,222.475,225.818,229.862,232.859,235.109,239.46,242.457,244.707,249.416,253.841,256.006,260.506,262.756,269.784,274.329,278.816,281.515,286.165,289.767,292.017,294.267,298.263,300.513,307.289,314.388,319.323,325.326,327.576,331.927,334.924,337.174,341.607,346.107,348.409,352.909,355.159,362.656,364.906,371.419,375.582,379.083,381.333,385.403,389.493,391.948,396.03,400.698,403.25,407.285,409.927,414.051,418.551,420.801,424.115,427.181,431.712,438.715,440.965,445.686,449.72,452.47,456.466,458.716,463.227,467.8,472.546" y="344.112" svg_rhmargin="475.543" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">follow-up period (mfp) of 44.6 months, a wmSR of 98.3 % was calculated from data pub-</text>
  <text x="149.149,151.8,154.376,157.899,162.427,166.552,171.052,173.302,176.196,180.737,183.734,185.984,190.559,194.592,197.309,199.76,203.893,208.379,211.066,214.567,216.817,223.505,225.964,228.663,233.163,235.413,239.85,245.349,249.849,252.099,254.676,258.765,263.485,267.985,270.235,274.809,278.844,281.559,284.011,288.145,292.631,295.317,298.818,301.068,307.757,310.216,312.914,317.414,319.664,324.119,328.653,333.153,335.403,338.127,345.186,349.602,352.154,356.35,360.837,363.523,366.568,369.426,371.676,373.926,380.491,384.526,387.275,391.271,393.521,397.87,400.867,403.117,407.527,412.027,414.277,418.852,422.886,425.601,428.053,432.186,436.673,439.358,442.859,445.109,447.689,451.855,456.085,460.585,462.835,465.559,472.642" y="354.912" svg_rhmargin="475.639" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">lished for patients with oLp (100 patients with 302 implants). Data of 27 patients (152 im-</text>
  <text x="150.635,155.051,157.604,161.8,166.287,168.972,172.018,175.015,177.265,183.953,186.412,189.11,193.61,195.86,201.414,207.417,209.667,212.753,216.784,221.178,225.293,229.383,231.852,235.976,240.476,242.726,249.503,256.602,261.537,267.54,269.79,274.141,277.138,279.388,283.821,288.321,290.09,294.59,296.84,304.337,306.587,309.481,313.871,316.514,318.974,323.367,330.055,332.788,337.301,341.801,344.051,351.249,354.594,359.094,361.344,365.694,368.691,370.941,375.181,379.765,381.931,386.431,388.681,395.709,400.254,404.74,407.438,412.089,415.618,417.868,420.118,424.848,429.388,432.385,434.635,438.819,443.319,445.569,450.143,454.178,456.893,459.345,463.479,467.965,470.651,474.152" y="365.712" svg_rhmargin="476.402" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">plants) with EB revealed wmSR of 98.7 % following mfp of 32.6 months. For 71 patients </text>
  <text x="155.471,158.242,162.651,167.044,171.544,173.794,176.518,183.577,187.993,190.545,194.741,199.228,201.914,204.959,207.956,210.206,216.894,219.353,222.052,226.552,228.802,233.666,236.088,241.162,243.412,245.662,252.44,259.538,264.474,270.477,272.727,279.238,283.402,286.903,289.153,293.712,298.138,300.483,304.983,307.233,314.73,316.98,319.875,324.265,326.907,329.367,333.76,340.448,343.181,347.694,352.194,354.444,358.44,360.69,367.888,371.231,375.731,377.981,382.332,385.329,387.579,391.811,396.053,398.399,402.899,405.149,412.178,416.723,421.209,423.907,428.558,432.159,434.409,436.659,440.856,445.383,449.883,452.133,455.028,459.568,462.565,464.815,469.315" y="376.512" svg_rhmargin="471.565" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">(272 implants) with SjS, wmSR was 94.2 % following a mfp of 45.2 months, and for 6 </text>
  <text x="148.47,153.045,157.079,159.795,162.247,166.38,170.867,173.552,177.053,179.303,181.827,186.536,191.036,193.286,196.01,203.068,207.484,210.037,214.233,218.72,221.405,224.451,227.448,229.698,236.386,238.845,241.543,246.043,248.293,251.841,256.89,260.886,263.136,265.386,272.164,279.261,284.197,290.2,292.45,298.962,303.125,306.626,308.876,313.411,317.288,319.056,323.556,325.806,333.303,335.553,339.631,342.931,345.574,349.716,352.713,354.963,362.161,365.504,370.004,372.254,376.605,379.602,381.852,386.113,389.989,392.297,396.797,399.047,406.076,410.621,415.107,417.806,422.456,425.985,428.235,430.485,437.192,441.728,445.724,447.974,452.041,456.204,459.772,463.768,466.018,469.104,473.32" y="387.312" svg_rhmargin="476.317" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">patients (44 implants) with sSc, wmSR was 97.7 % after mfp of 37.5 months. One case re-</text>
  <text x="148.611,153.233,157.773,161.151,163.653,165.903,170.446,174.946,177.196,181.741,186.277,190.273,192.523,197.097,201.131,203.847,206.299,210.431,214.918,217.42,219.67,223.784,227.93,231.921,236.421,238.671,245.359,247.817,250.516,255.016,257.266,262.119,266.115,268.365,270.971,273.785,280.153,284.653,286.903,289.627,296.685,301.101,303.654,307.85,312.337,315.022,318.068,321.065,323.315,327.478,330.979,333.229,339.624,343.56,346.204,348.706,350.956,355.116,358.617,360.867,364.378,369.919,375.418,377.668,380.254,384.754,387.004,389.729,396.786,401.203,403.755,407.952,412.438,415.124,418.17,421.167,423.417,426.941,431.46,435.853,442.246,446.371,450.871,453.121,457.21,461.929,466.429,468.679,476.176" y="398.112" svg_rhmargin="478.426" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">port on one patient each with Pe (two implants) as well as sLE (6 implants) showed 100 % </text>
  <text x="150.651,155.587,161.59,163.84,166.735,171.123,173.767,176.226,180.62,187.308,190.041,194.554,199.054,201.304,205.339,207.841,210.091,212.558,216.673,220.836,224.399,226.901,229.151,233.674,238.174,240.424,247.453,251.997,256.484,259.183,263.833,267.362,269.612" y="408.912" svg_rhmargin="271.862" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">SR following at least 24 months. </text>
  <text x="271.863,276.891,282.01,289.651,297.19,301.767,306.068,310.559,313.556" y="408.912" svg_rhmargin="315.806" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:9.0px;font-style:NORMAL;font-weight:bold;">Summary: </text>
  <text x="315.803,319.038,326.096,330.512,333.065,337.261,341.747,344.249,346.499,350.099,354.883,358.265,362.953,365.417,369.931,374.021,376.523,378.773,381.94,385.974,388.617,392.746,396.247,398.497,402.849,405.846,408.096,412.67,416.705,419.42,421.872,426.006,430.492,433.178,436.679,438.929,445.618,448.077,450.775,455.275,457.525,461.962,467.461,471.888,474.138" y="408.912" svg_rhmargin="476.388" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Implant survival rates of patients with oLp, </text>
  <text x="147.081,151.934,155.968,158.218,160.468,166.021,172.051,174.301,176.551,181.416,183.837,188.913,191.163,193.413,196.921,202.462,207.961,210.211,214.75,217.747,219.997,223.545,228.594,232.59,234.84,239.044,242.131,246.127,248.377,252.471,257.002,264.061,268.635,272.841,276.01,280.074,284.491,286.96,290.956,293.206,295.838,300.338,302.588,305.286,309.805,314.38,317.948,321.944,324.194,328.543,331.54,333.79,338.318,342.434,346.523,348.983,351.681,356.135,360.635,362.885,367.46,371.494,374.21,376.662,380.794,385.281,387.968,391.496,393.746,395.996,400.727,405.267,408.264,410.514,413.239,420.297,424.714,427.266,431.462,435.948,438.37,441.46,446.037,449.103,453.678,457.24,459.939,464.467,468.531,471.246,473.712,477.708" y="419.712" svg_rhmargin="479.958" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Pe, EB, SjS, sLE or sSc are comparable to those of healthy patients. For implant-prosthetic </text>
  <text x="148.749,151.836,155.87,160.483,164.546,169.018,171.643,174.295,176.754,179.503,183.538,186.253,188.696,193.241,197.741,199.991,204.342,207.339,209.589,214.164,218.198,220.913,223.366,227.499,231.985,234.671,238.172,240.422,247.111,249.57,252.268,256.768,259.018,263.872,267.868,270.118,274.313,278.84,283.34,285.59,289.098,294.639,300.138,302.388,306.914,311.414,313.664,317.759,322.304,326.852,330.745,333.242,337.914,341.392,343.835,348.38,353.039,356.54,358.79,362.861,367.056,371.556,373.806,378.411,382.407,384.657,389.456,392.624,396.575,403.365,407.865,410.115,414.697,419.246,423.242,425.492,428.123,432.623,434.873,437.427,441.572,445.555,450.055,452.305,456.656,459.653,461.903,465.505,470.159,473.042" y="430.512" svg_rhmargin="476.039" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">rehabilitation of patients with Pe and sLE no conclusions can be drawn due to lack of suf-</text>
  <text x="153.854,158.827,162.862,165.314,169.447,173.934,176.436,178.686,182.578,185.229,187.961,192.68,195.145,199.213,203.303,205.805,208.055,212.777,216.811,219.561,223.689,225.939,228.189,231.423,238.481,242.898,245.451,249.646,254.133,256.555,259.645,264.222,267.287,271.862,275.424,278.123,282.651,286.716,289.431,291.896,295.892,298.142,300.956,304.043,308.157,312.192,314.997,322.034,326.168,330.655,333.157,335.407,340.217,344.893,347.361,351.927,355.865,358.516,361.248,365.784,369.914,373.415,375.665,378.754,382.741,387.311,391.517,394.566,399.258,401.991,406.504,411.004,413.254,417.782,421.897,425.987,428.446,431.145,435.599,440.099,442.349,446.924,450.958,453.673,456.126,460.259,464.745,467.432,470.933" y="441.312" svg_rhmargin="473.183" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">ficient clinical data. Implant-prosthetic treatment guidelines regarding healthy patients </text>
  <text x="151.072,154.596,159.115,163.628,168.295,170.755,175.255,177.505,182.109,186.105,188.355,191.917,194.731,198.023,200.488,204.57,207.161,209.638,214.138,216.388,219.282,223.671,226.314,228.774,233.168,239.561,243.686,248.393,250.643,252.893,257.406,261.932,264.434,266.684,269.996,273.083,277.208,281.79,286.338,290.471,294.958,297.46,299.71,302.796,306.933,311.002,315.092,317.734,320.236,322.486,325.06,328.561,330.811,333.9,338.037,342.132,346.664,353.973,361.011,365.144,369.671,374.237,378.361,382.861,385.111,387.844,392.344,394.594,399.169,403.203,405.918,408.37,412.503,416.99,419.675,423.176,425.426,429.505,432.714,435.634,439.771,443.854,446.496,450.62,455.12,457.37,464.058,466.517,469.216,473.716" y="452.112" svg_rhmargin="475.966" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">should be strictly followed, but frequent recall is recommended in patients affected with </text>
  <text x="258.315,262.752,268.251,272.678,274.928,277.178,282.044,284.465,289.54,291.79,294.04,299.593,305.623,307.873,310.123,315.121,320.17,324.166,326.416,328.666,333.518,337.514,339.764,344.304,347.301,349.551,353.059,358.601,364.224" y="462.912" svg_rhmargin="366.474" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">oLp, SjS, EB, SSc, Pe or sLE.</text>
  <text svg_rhmargin="464.649" x="160.137,165.043,167.776,172.325,176.406,180.402,182.652,185.35,189.877,193.873,196.123,199.703,204.255,207.818,210.46,214.585,221.706,225.74,228.456,230.92,234.916,237.166,240.252,244.282,248.971,251.422,255.461,261.959,264.209,270.723,274.886,278.387,280.637,285.165,289.665,292.167,294.417,297.503,301.491,306.18,308.756,312.318,314.96,319.102,322.189,326.313,331.022,333.272,335.522,340.048,344.548,346.798,349.885,353.874,358.563,361.138,364.701,367.515,370.684,374.719,377.434,379.877,384.422,388.922,391.172,395.665,400.431,407.439,412.044,416.184,419.181,421.431,424.007,427.508,429.758,433.7,438.214,442.311,444.937,447.49,451.554,455.97,458.439,462.399,464.649" y="236.11199999999997" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Since the systematic review was not registered, no registration number is available. </text>
  <text x="507.939" y="236.11199999999997" svg_rhmargin="512.439" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">2</text>
  <text x="76.991,81.491,83.741,85.991,88.241,90.491,93.223,97.71,100.525,103.591,108.194,112.776,117.338,121.42,124.135,126.578,131.123,135.623,136.225,136.828" y="487.952" svg_rhmargin="139.078" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">3 introduction </text>
  <text svg_rhmargin="122.573" y="487.952" x="90.491,93.66,97.695,100.41,102.853,107.398,112.018,116.108,118.577,122.573" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">rationale </text>
  <text x="153.466,158.372,161.105,165.654,169.735,173.731,175.981,180.507,185.007,187.257,192.07,196.745,199.214,203.779,207.717,210.368,213.101,217.637,221.766,225.267,227.517,230.605,234.594,239.163,243.369,246.417,251.11,253.843,258.356,262.856,265.106,267.831,274.888,279.305,281.858,286.054,290.54,293.042,295.292,298.106,301.193,305.308,309.342,312.148,319.185,323.318,327.805,330.307,332.557,336.906,339.903,342.153,346.727,350.762,353.477,355.93,360.063,364.549,367.235,370.736,372.986,379.676,382.134,384.833,389.333,391.583,396.02,401.519,405.946,408.196,410.446,415.299,419.332,421.582,423.832,429.385,435.415,437.665,439.915,444.78,447.202,452.276,454.526,456.776,460.285,465.825,471.324" y="487.952" svg_rhmargin="473.574" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Since no guidelines regarding implant treatment of patients with oLp, Pe, EB, SjS, sLE </text>
  <text x="155.677,160.217,163.214,165.464,169.012,174.061,178.057,180.307,184.315,188.999,191.574,195.138,197.64,199.89,204.415,208.955,211.952,214.202,218.409,221.496,225.492,227.742,231.835,236.38,240.867,243.681,246.85,250.948,253.681,258.208,262.9,265.365,269.433,273.467,276.183,278.626,283.171,287.83,291.331,293.581,298.149,302.215,307.458,311.994,316.117,320.825,323.075,325.325,328.024,332.552,336.548,338.798,342.894,345.619,352.621,354.871,359.22,362.217,364.467,367.166,371.877,374.452,377.953,380.203,383.784,388.336,391.899,394.542,398.666,405.787,409.821,412.536,415.001,418.997,421.247,424.333,428.364,433.052,435.504,439.543,446.041,448.291,452.642,455.639,457.889,460.588,465.116,469.112" y="498.752" svg_rhmargin="471.362" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">or sSc exist nor are contraindications defined, the aim of this systematic review of the </text>
  <text x="149.614,152.266,154.725,157.368,161.509,164.678,168.712,171.552,176.335,179.422,183.418,185.668,192.18,196.343,199.844,202.094,204.729,209.229,211.479,214.566,218.597,222.991,227.106,231.196,233.785,236.035,238.285,244.789,249.316,253.382,256.08,260.608,264.749,267.746,269.996,274.571,278.605,281.321,283.773,287.906,292.392,295.079,298.58,300.83,304.432,309.087,312.295,315.215,319.356,322.649,325.382,329.895,334.395,336.645,339.959,343.024,347.556,354.558,356.808,360.871,365.474,369.859,374.253,378.249,380.499,387.535,391.668,396.154,398.869,401.313,405.858,410.394,414.518,419.018,421.268,425.96,428.536,432.104,436.22,440.382,443.951,448.079,451.58,453.83,461.051,463.481,468.195,472.674,475.176" y="509.552" svg_rhmargin="477.426" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">literature was to reveal, whether patients suffering from above mentioned diseases might </text>
  <text svg_rhmargin="403.441" x="221.347,225.952,230.084,234.62,238.687,243.644,246.146,248.396,251.708,254.773,259.305,266.307,268.557,271.28,278.338,282.754,285.307,289.503,293.99,296.411,299.501,304.078,307.143,311.718,315.281,317.979,322.498,327.102,331.658,336.203,340.69,343.405,345.87,349.866,352.116,355.202,359.237,363.849,367.912,372.383,375.01,377.661,380.12,382.87,386.904,389.619,392.063,396.608,401.191,403.441" y="487.952" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">benefit from implant-prosthodontic rehabilitation. </text>
  <text x="507.939" y="487.952" svg_rhmargin="512.439" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">3</text>
  <text x="76.991,81.491,83.741,85.991,88.241,90.491,94.989,99.453,101.915,106.053,110.134,112.85,115.316,119.71,123.838,127.339,149.705,158.549,163.26,165.724,169.715,174.215,176.465,179.19,186.248,190.664,193.217,197.413,201.9,204.402,206.652,210.252,215.035,218.417,223.105,225.569,230.082,234.172,236.674,238.924,242.092,246.126,248.769,252.897,256.398,258.648,265.044,269.185,272.272,276.268,278.518,281.604,285.775,290.397,294.937,298.315,300.958,305.082,309.582,311.832,314.564,319.064,321.314,325.889,329.924,332.639,335.091,339.224,343.711,346.397,349.898,352.148,355.75,360.405,363.613,366.534,370.675,373.967,376.7,381.213,385.713,387.963,391.277,394.343,398.875,405.877,408.127,415.12,419.682,423.777,428.394,432.475,437.001,439.751,443.948,448.484,452.608,457.12,461.792,465.293,467.543,472.085,475.082" y="534.592" svg_rhmargin="477.332" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">4 objectives Which implant survival rates were reported in patients suffering from mucocutaneous or </text>
  <text x="207.999,212.042,216.569,219.202,223.645,226.377,231.196,236.246,240.433,247.743,254.865,258.899,261.532,266.073,269.468,273.968,276.218,280.911,283.486,287.054,291.169,295.332,298.9,303.029,306.53,308.78,313.218,318.717,323.144,325.394,327.644,332.497,336.531,338.781,341.031,346.584,352.614,354.864,357.114,361.978,364.4,369.474,371.724,373.974,377.484,383.024,388.523,390.773,395.313,398.31,400.56,404.106,409.156,412.795" y="545.392" svg_rhmargin="416.791" style="fill:#000000;font-family:CRUCZX+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">autoinflammatory diseases oLp, Pe, EB, SjS, sLE or sSc?</text>
  <text x="151.639,156.48,159.397,165.423,171.797,174.299,176.549,178.799,183.373,187.407,190.122,192.574,196.707,201.194,203.879,207.38,209.63,213.234,217.889,221.096,224.017,228.158,231.45,234.183,238.697,243.197,245.447,248.76,251.826,256.357,263.359,265.609,270.044,275.543,279.971,282.221,284.471,289.324,293.358,295.608,297.858,303.411,309.441,311.691,313.941,318.806,321.227,326.302,328.552,330.802,334.311,339.851,345.35,347.6,352.14,355.137,357.387,360.934,365.984,369.98,372.23,375.551,380.173,384.73,389.242,393.91,396.463,400.497,403.212,405.656,410.201,414.369,417.199,419.701,421.951,425.843,428.494,431.227,435.945,438.41,442.478,446.569,449.071,451.321,455.991,459.559,463.555,465.805,470.154,473.151" y="556.192" svg_rhmargin="475.401" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">PICO: patients suffering from oLp, Pe, EB, SjS, sLE or sSc (population); clinical use of </text>
  <text x="152.756,157.322,161.454,165.942,168.691,172.781,175.283,177.533,180.256,187.314,191.73,194.284,198.48,202.966,205.387,208.477,213.054,216.12,220.695,224.257,226.956,231.475,236.078,240.635,245.18,249.666,252.382,254.847,258.843,261.093,264.179,268.213,272.825,276.889,281.361,283.986,286.637,289.097,291.847,295.88,298.597,301.039,305.584,310.084,312.334,315.227,317.959,322.446,325.089,329.23,332.612,337.006,341.14,345.626,348.341,350.784,355.329,359.498,362.328,364.83,367.08,371.173,375.718,380.204,383.019,386.085,390.474,392.976,395.226,400.012,403.077,407.59,412.159,416.75,420.251,422.501,428.895,433.037,436.124,440.12,442.37,444.922,449.067,453.05,457.812,460.545,465.058,469.531,472.033" y="566.992" svg_rhmargin="474.283" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">dental implant-prosthodontic rehabilitation (intervention); control groups were lacking; </text>
  <text svg_rhmargin="369.899" x="254.889,257.613,264.672,269.089,271.641,275.838,280.323,282.825,285.075,288.675,293.459,296.841,301.529,303.993,308.507,312.596,315.098,317.348,320.516,324.55,327.193,331.189,333.439,335.983,340.496,345.022,347.673,351.768,356.3,363.337,366.902,369.899" y="534.592" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">implant survival rate (outcome) </text>
  <text x="503.51,507.866,510.116,512.366" y="534.592" svg_rhmargin="516.866" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">3, 4</text>
  <text x="76.991,81.491,83.741,85.991,88.241,90.491,97.528,101.593,104.292,108.811,113.414,118.103,121.604,123.854" y="592.032" svg_rhmargin="126.104" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">5 methods </text>
  <text y="602.832" svg_rhmargin="136.342" x="90.491,95.068,98.134,102.634,105.267,109.884,113.979,118.369,120.871,123.121,127.315,131.842" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">protocol and</text>
  <text svg_rhmargin="132.615" y="592.032" x="90.491,93.578,97.566,102.256,104.831,108.393,111.208,114.377,118.411,121.126,123.57,128.115,132.615" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">registration </text>
  <text x="151.4,157.898,160.148,163.729,168.281,171.844,174.487,178.611,185.732,189.766,192.482,194.946,198.942,201.192,203.843,206.302,208.945,213.086,216.255,220.29,223.129,227.912,230.999,234.995,237.245,240.812,244.927,249.134,252.217,256.208,260.708,262.958,267.63,271.107,273.84,278.354,282.854,285.104,293.352,298.881,303.818,310.348,313.345,315.595,319.791,324.318,328.818,331.068,334.636,338.751,342.958,346.041,350.032,354.532,356.782,359.425,363.566,366.948,373.95,376.2,380.293,384.825,391.832,396.303,399.037,403.657,407.691,410.406,412.85,417.395,422.054,425.555,427.805,430.361,433.929,438.055,442.051,444.301,449.248,453.312,457.729,460.197,464.193,466.443,470.391,473.388" y="592.032" svg_rhmargin="475.638" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">A systematic literature search using MESH- and search term combinations (see Table 1) </text>
  <text x="185.246,191.758,195.921,199.422,201.672,206.294,210.435,213.689,216.584,221.124,224.506,231.544,235.668,240.168,242.418,245.052,249.552,251.802,254.271,258.837,262.97,267.456,270.172,272.785,276.102,280.602,282.852,287.365,291.938,296.354,299.006,301.471,305.539,309.574,312.289,314.731,319.276,323.936,327.437,329.687,336.726,340.851,344.916,347.631,350.364,354.878,359.378,361.628,364.326,368.854,372.85,375.1,377.831,382.38,386.273,388.775,393.446,396.923,399.367,403.912,408.412,410.662,414.803,418.095,420.555,423.197,427.338,430.63,433.166,437.294" y="602.832" svg_rhmargin="439.544" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">was performed to identify publications meeting the inclusion criteria.</text>
  <text svg_rhmargin="419.733" x="205.053,210.8,215.51,218.086,221.587,223.837,227.418,231.971,235.534,238.176,242.3,249.422,253.455,256.171,258.636,262.632,264.882,267.967,271.998,276.686,279.138,283.177,289.675,291.925,298.438,302.601,306.102,308.352,312.881,317.381,319.883,322.133,325.218,329.207,333.896,336.471,340.034,342.676,346.818,349.905,354.029,358.529,360.779,363.512,368.012,370.262,374.458,378.916,383.416,385.666,390.389,394.423,397.173,401.237,405.791,409.955,413.522,417.483,419.733" y="592.032" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">This systematic review was not registered in any database. </text>
  <text x="507.939" y="592.032" svg_rhmargin="512.439" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">4</text>
  <text x="76.991,81.491,83.741,85.991,88.241,90.491,94.428,97.08,99.509,104.198,106.747,111.218,113.844,116.496,118.954,121.773,126.273" y="627.873" svg_rhmargin="128.523" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">6 eligibility </text>
  <text svg_rhmargin="116.993" y="627.873" x="90.491,94.631,97.923,100.383,103.029,107.169,110.461,112.997,116.993" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">criteria </text>
  <text x="148.569,151.812,156.36,160.254,162.751,167.423,170.9,173.343,177.888,182.388,184.638,188.989,191.986,194.236,198.748,203.321,207.738,210.389,212.854,216.922,220.956,223.672,226.115,230.66,235.319,238.82,241.07,244.159,248.33,252.952,257.492,260.87,263.586,266.319,270.832,275.332,277.582,282.127,286.627,288.877,293.452,297.486,300.202,302.654,306.787,311.274,313.959,317.46,319.71,326.399,328.859,331.557,336.057,338.307,342.744,348.243,352.67,354.92,357.17,362.024,366.057,368.307,370.557,376.111,382.14,384.39,386.64,391.505,393.926,399.001,401.251,403.501,407.009,412.551,418.05,420.3,424.838,427.835,430.085,433.633,438.682,442.678,444.928,448.251,452.873,457.429,461.942,466.609,469.162,473.221" y="627.873" svg_rhmargin="476.218" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Inclusion of publications reporting on patients with oLp, Pe, EB, SjS, sLE or sSc (popula-</text>
  <text x="147.507,150.222,152.666,157.211,161.379,164.277,166.527,168.777,173.551,178.078,182.644,186.785,189.833,194.295,198.738,201.471,205.984,210.484,212.734,216.627,219.278,222.012,226.73,229.194,233.262,237.353,239.855,242.105,246.775,250.344,254.34,256.59,260.938,263.935,266.185,270.751,274.885,279.371,282.121,286.211,288.713,290.963,293.686,300.745,305.161,307.713,311.909,316.396,318.818,321.907,326.485,329.55,334.125,337.688,340.386,344.914,348.978,351.695,354.159,358.155,360.405,363.491,367.526,372.137,376.202,380.673,383.298,385.949,388.409,391.159,395.193,397.909,400.351,404.896,409.396,411.646,414.539,417.271,421.758,424.401,428.542,431.924,436.318,440.452,444.938,447.654,450.096,454.641,458.81,461.807,464.057,468.254,472.781,477.281" y="638.673" svg_rhmargin="479.531" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">tion), undergoing clinical use of dental implant-prosthetic rehabilitation (intervention) and </text>
  <text x="149.121,152.208,156.239,160.633,164.748,168.839,171.49,174.222,178.736,183.236,185.486,189.049,191.888,196.461,201.022,205.522,207.772,212.337,216.467,219.943,222.372,227.165,231.821,234.071,236.321,240.389,244.872,248.905,251.155,253.405,257.889,262.023,266.55,271.115,275.256,278.033,280.283,282.533,287.027,291.792,298.8,303.405,307.546,310.543,312.793,317.143,320.14,322.39,326.965,331.0,333.715,336.168,340.3,344.787,347.472,350.973,353.223,357.421,361.948,366.448,368.698,371.423,378.481,382.897,385.45,389.647,394.133,396.819,400.421,402.671,404.921,407.816,412.205,414.848,417.307,421.702,428.074,431.147,435.716,440.216,442.466,447.088,451.23,454.522,456.965,461.568,466.068,468.318,472.669,475.666" y="649.473" svg_rhmargin="477.916" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">revealing study design, age, gender, number of patients and implants, follow-up period of </text>
  <text x="153.302,157.843,160.84,163.09,167.099,171.47,175.553,179.677,183.802,188.495,191.227,195.741,200.241,202.491,206.798,211.298,213.548,220.577,225.122,229.609,232.307,236.957,240.458,242.708,246.906,251.433,255.933,258.183,260.907,267.966,272.382,274.934,279.13,283.617,286.119,288.369,291.969,296.752,300.135,304.823,307.287,311.8,315.89,318.392,320.642,323.81,327.844,330.486,334.482,336.732,339.276,343.789,348.315,350.967,355.062,359.593,366.63,370.195,373.025,375.527,377.777,382.288,386.86,391.277,393.928,396.393,400.461,404.496,407.211,409.654,414.199,418.699,420.949,425.553,429.619,432.433,438.826,442.951,447.085,451.585,453.835,458.009,462.442,466.986,471.486" y="660.273" svg_rhmargin="473.736" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">or exceeding 12 months and implant survival rate (outcome); publication between 1980 </text>
  <text x="154.08,158.276,162.803,167.303,169.553,176.161,180.243,182.876,187.376,191.981,196.122,199.119,201.369,205.884,209.971,213.854,218.354,220.604,223.338,227.838,230.088,235.64,240.153,244.761,247.414,249.988,253.513,258.013,260.263,264.803,267.8,270.05,276.663,280.804,284.187,291.307,295.504,300.004,302.254,304.807,309.002,313.516,318.328,323.034,327.103,331.587,335.426,337.928,340.178,343.265,347.436,352.058,356.598,359.976,362.692,365.424,369.938,374.438,376.688,381.233,385.733,387.983,392.077,396.609,403.667,408.242,412.448,415.74,418.316,421.881,426.426,430.926,433.176,437.527,440.524,442.774,445.499,452.557,456.973,459.526,463.723,468.209,470.711" y="671.073" svg_rhmargin="472.961" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">and October 2017 in English or German language; reporting on comparison of implant </text>
  <text x="216.265,219.867,224.65,228.032,232.721,235.184,239.697,243.788,246.29,248.54,251.709,255.743,258.386,262.514,266.015,268.265,272.871,276.936,279.751,286.144,290.269,294.402,298.902,301.152,305.68,309.796,313.885,316.344,319.043,323.497,327.997,330.247,334.443,338.97,343.47,345.72,349.798,353.006,355.926,360.063,364.146,366.788,370.913,375.413,377.663,382.238,386.272,388.987,391.439,395.572,400.059,402.745,406.274" y="681.873" svg_rhmargin="408.524" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">survival rates between healthy and affected patients.</text>
  <text x="152.31,157.849,162.221,166.114,168.612,173.284,176.761,179.204,183.749,188.249,190.499,194.85,197.847,200.097,204.609,209.182,213.598,216.251,218.715,222.783,226.818,229.533,231.976,236.521,241.18,244.783,247.033,249.283,251.895,254.892,257.142,261.669,266.169,268.671,270.921,277.958,282.083,286.148,288.863,291.596,296.11,300.61,302.86,305.558,310.086,314.082,316.332,319.063,323.612,327.504,330.006,334.678,338.155,340.598,345.144,349.644,351.894,356.034,359.327,361.785,364.429,368.57,371.862,374.398,378.598,380.848,383.098,387.638,390.635,392.885,395.499,398.496,400.746,403.64,408.181,411.563,418.684,422.717,425.434,427.876,432.421,436.921,439.171,443.522,446.519,448.769,455.89,459.98,462.632,465.062,469.48" y="692.673" svg_rhmargin="472.477" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Exclusion of publications, if not meeting the inclusion criteria, or if formation of malig-</text>
  <text x="177.656,182.277,186.472,190.96,193.462,195.712,198.551,203.317,210.345,214.857,219.641,222.638,224.888,227.621,232.121,234.371,237.069,241.597,245.593,247.843,252.371,256.486,260.653,265.153,267.403,271.599,276.126,280.626,282.876,287.412,291.55,295.533,300.033,302.283,305.37,309.358,314.047,316.49,321.035,325.535,327.785,330.517,335.004,337.647,341.788,345.042,347.963,352.105,355.192,359.316,363.816,366.066,372.754,375.212,377.911,382.411,384.661,387.386,394.444,398.86,401.413,405.609,410.095,412.597,414.847,418.447,423.231,426.613,431.301,433.765,438.278,442.369,444.884" y="703.473" svg_rhmargin="447.134" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">nant tumour in the head and neck region interfered with implant survival.</text>
  <text x="149.709,154.615,157.349,161.897,165.979,169.975,172.225,174.922,179.633,182.207,185.708,187.958,191.54,196.093,199.655,202.298,206.422,213.543,217.578,220.293,222.758,226.754,229.004,232.089,236.119,240.807,243.26,247.298,253.796,256.046,262.56,266.723,270.224,272.474,277.003,281.503,284.005,286.255,289.34,293.329,298.018,300.593,304.156,306.798,310.939,314.026,318.151,322.651,324.901,327.633,332.133,334.383,338.58,343.038,347.538,349.788,354.511,358.545,361.295,365.359,369.913,374.076,377.645,381.678,383.928,386.178,388.877,393.404,397.4,399.65,404.226,407.291,411.791,414.426,419.043,423.137,427.526,430.028,432.278,434.852,438.353,440.603,445.131,449.631,452.133,454.383,458.322,462.836,466.934,469.56,472.081" y="725.073" svg_rhmargin="475.078" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">Since this systematic review was not registered in any database, the protocol is not avail-</text>
  <text svg_rhmargin="344.663" x="280.125,284.189,288.605,291.074,295.07,297.32,301.863,306.363,308.613,312.609,314.859,321.251,325.298,329.873,333.35,335.81,338.452,342.413,344.663" y="627.873" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">able on a website. </text>
  <text x="507.939" y="627.873" svg_rhmargin="512.439" style="fill:#000000;font-family:EHOOBT+TimesNewRomanPSMT;font-size:9.0px;font-style:NORMAL;font-weight:normal;">4</text>
  <text x="72.866,77.778,81.829,86.308,88.616,92.166,94.166,98.388" y="173.61800000000005" svg_rhmargin="100.388" style="fill:#171615;font-family:CRUCZX+TimesNewRomanPS-BoldMT;font-size:8.0px;font-style:NORMAL;font-weight:bold;">Table 2.</text>
  <text y="173.61800000000005" svg_rhmargin="166.19" x="102.385,106.753,112.433,115.153,119.581,126.993,132.771,134.771,138.354,142.41,146.12,149.695,153.95,156.34,158.662,161.862,164.19" style="fill:#171615;font-family:EHOOBT+TimesNewRomanPSMT;font-size:8.0px;font-style:NORMAL;font-weight:normal;">PRISMA checklist.</text>
 </g>
</svg>
